Non-invasive measurement of analytes

Abstract

This invention provides devices, compositions and methods for determining the concentration of one or more metabolites or analytes in a biological sample, including cells, tissues, organs, organisms, and biological fluids. In particular, this invention provides materials, apparatuses, and methods for several non-invasive techniques for the determination of in vivo blood glucose concentration levels based upon the in vivo measurement of one or more biologically active molecules found in skin.

Description

RELATED APPLICATIONS [0001] This invention is a continuation in part of U.S. Ser. No. 10 / 617,915, filed on Jul. 10, 2003, which is a continuation in part of U.S. Ser. No. 10 / 616,533, filed on Jul. 9, 2003, which claims priority to U.S. provisional patent application Ser. No. 60 / 425,488, filed Nov. 12, 2002, and this application also claims priority to Ser. No. 60 / 438,837, filed Jan. 9, 2003, Ser. No. 60 / 439,395, filed Jan. 10, 2003, Ser. No. 60 / 447,603, filed Feb. 13, 2003, and Ser. No. 60 / ______, filed on Oct. 31, 2003, each of which is incorporated by reference in its entirety.FIELD OF THE INVENTION [0002] This invention provides devices, compositions and methods for determining the concentration of one or more metabolites or analytes in a biological sample, including cells, tissues, organs, organisms, and biological fluids. In particular, this invention provides materials, apparatuses, and methods for several non-invasive techniques for the determination of in vivo blood glucose ...

AI Technical Summary

Benefits of technology

[0393] In one embodiment, a small molecule metabolic reporter (i.e., Glucose Oxidase-Labeled Fluorophore: GO-LF), when brought in contact with glucose, forms a fluorescent species. The GO-LF molecule is in the form of glucose oxidase protein whereby a fluorescent cofactor analog is incorporated as a substituent molecule (SubMol) to the enzyme cofactor flavin adenine dinucleotide (FAD). One advantage of the present invention is the increased sensitivity of 10-100 times the former visible color reaction, smaller analyte concentration requirements (pM vs. μM or mM of glucose), and greater simplicity of the chemical strip system (i.e., a single reagent versus multiple reagents as described in detail herein). This sensor or reader measuring the strip response requires less sample volume, less sensitivity, and less power than previous strips while yielding improved accuracy.

Problems solved by technology

Invasive forms of self-testing are painful and fraught with a multitude of psychosocial hurdles, and are resisted by most diabetics.

However, other endogenous substances including, but not limited to, water, lipids, proteins, and hemoglobin are known to absorb energy, particularly infrared light and can easily obscure the relatively weak glucose signal.

While putatively non-invasive, these technologies have yet to be demonstrated as effective in clinical testing.

In keeping with its nearly noninvasive description, this technology is commonly associated with some discomfort and requires at least twice daily calibrations against conventional blood glucose measurements (e.g. invasive lancing).

Although technologically innovative, these in situ sensors have had limited success.

Implantable glucose oxidase (“GO”) sensors have been limited by local factors causing unstable signal output, whereas optical sensors must overcome signal obfuscation by blood constituents as well as interference by substances with absorption spectra similar to glucose.

Moreover, inflammation associated with subcutaneous monitoring may contribute to systematic errors requiring repositioning, recalibration or replacement, and more research is needed to evaluate the effects of variable local inflammation at the sensor implantation site on glucose concentration and transit time.

Images